Clinical trials: sponsored by Peking University
Lung Cancer, Lung Infection
Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath
The goal of this observational study is to develop an advanced expiratory algorithm model utilizing exhaled breath volatile organic compound (VOC) marker molecules.
- Conditions
- Lung Cancer, Lung Infection, COPD, Bronchitis
- Trial name
- NCT06528418
- Testing
- Gas chromatography-mass spectrometry(GC-MS) and micro Gas Chromatography-photoionisation detector (μGC-PID) system
- Where
- China
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- ChromX Health
Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.
The goal of this clinical trial is to learn the efficaty and safety of BC001 in combination with Sintilimab and XELOX in treating patients with advanced or metastatic GC/GEJ.
- Trial name
- NCT06773312
- Testing
- BC001+Sintilimab+XELOX
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.
Sepsis
Clinical Trial to Evaluate MDW for Early Detection of Sepsis
This study is intended to clinically verify Monocyte Distribution Width (MDW) parameter of DxH 900 Hematology Analyzer for use in early detection and risk assessment of sepsis, severe sepsis, and septic shock in critically ill…
- Trial name
- NCT06267742
- Testing
- Complete Blood Count (CBC) with Differential
- Where
- 3 sites in China
- Volunteers
- 2,200 people
- Sponsor
- Beckman Coulter, Inc.
Liver Fibrosis, Cirrhosis
FibroTouch Non-invasive Evaluation of Liver Fibrosis and Cirrhosis
This prospective and multicenter study is to determine the diagnostic performance (accuracy, specificity and sensitivity) of transient elastography (FibroTouch) for liver fibrosis assessment in chronic hepatitis B (CHB) patients…
- Conditions
- Liver Fibrosis, Cirrhosis, Chronic Hepatitis B
- Trial name
- NCT02476695
- Testing
- FibroTouch Examination, FibroScan Examination, Ultrasonic B Examination
- Where
- 15 sites in China
- Volunteers
- 412 people
- Sponsor
- Wuxi Hisky Medical Technology Co Ltd
Hypertension, MTHFR 677 CC or CT Genotype
China Stroke Primary Prevention Trial 2 for Participants With H-type Hypertension and MTHFR 677 CC/CT Genotype (CSPPT2-CC/CT)
This is a multi-center, randomized, double-blind, double-dummy, controlled clinical trial. This trial will include 32,000 Chinese men and women with hypertension (H-type hypertension), MTHFR 677 CC or CT genotype, elevated plasma…
- Conditions
- Hypertension, MTHFR 677 CC or CT Genotype, Elevated Plasma Homocysteine (Hcy≥10µmol/L), Insufficient Plasma Folate Levels (<12ng/mL)
- Trial name
- CSPPT2-CC/CT (NCT04974138)
- Testing
- Amlodipine besylate, Amlodipine besylate and folic acid
- Where
- 20 sites in China
- Volunteers
- 32,000 people
- Sponsor
- Shenzhen Ausa Pharmed Co.,Ltd
Hypertension, MTHFR 677 TT Genotype
China Stroke Primary Prevention Trial 2 for Participants With Hypertension and MTHFR 677 TT Genotype
This is a multi-center, randomized, double-blind, triple-dummy, controlled trial in 24,000 Chinese men and women with hypertension and MTHFR 677 TT genotype.
- Trial name
- CSPPT2-TT (NCT04974151)
- Testing
- Amlodipine besylate, Amlodipine besylate And Folic Acid, 5-methyltetrahydrofolate (5-MTHF)
- Where
- 20 sites in China
- Volunteers
- 24,000 people
- Sponsor
- Shenzhen Ausa Pharmed Co.,Ltd
Chronic Myelogenous Leukemia
TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients
The purpose of this single- arm, open-lable, dose escalation + dose expansion study is to evalulate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-678 in Chronic Myelogenous Leukemia patients who had…
- Trial name
- NCT05434312
- Testing
- TGRX-678
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Shenzhen TargetRx Co., Ltd.
Chronic Myeloid Leukemia, Accelerated Phase CML
TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients
A Phase II study evaluating the safety and efficacy of TGRX-678 in Chronic Myelogenous Leukemia (CML) patients in Accelerated phase (AP) and are relapsed or refractory from third-generation Tyrosine Kinase Inhibitor (TKI)…
- Trial name
- NCT06453902
- Testing
- TGRX-678
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shenzhen TargetRx Co., Ltd.
Colorectal Cancer (CRC)
Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Colorectal Cancer
This study, a single-center, open, single-dose clinical study, was designed to evaluate the safety and efficacy of IM96 CAR-T cells in treating patients with advanced colorectal cancer
- Trial name
- NCT06718738
- Testing
- IM96 CAR-T Cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
Chronic Hepatitis B
A Follow-up Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B
Studies have shown that chronic hepatitis B patients with low levels of HBsAg after nucleos(t)ide analog therapy have a higher chance of functional cure with sequential or combined pegylated interferon therapy, with about 30-50%…
- Trial name
- NCT06707922
- Testing
- Peginterferon α-2b Injection; Tenofovir Alafenamide Fumarate
- Where
- 30 sites in China
- Volunteers
- 350 people
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Chronic Hepatitis b
A Phase II Study of Subcutaneously Injected PD-L1 Antibody ASC22 in Chronic Hepatitis B Patients
The objective of this study is to evaluate the safety and efficacy of ASC22 in the treatment of chronic hepatitis B after single and multiple drug administration.
- Trial name
- NCT04465890
- Testing
- ASC22, sodium chloride
- Where
- China
- Volunteers
- 207 people
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
MECP2 Duplication Syndrome
A First-in-Human Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of a Novel CRISPR RNA-editing Therapy in Patients with Mecp2 Duplication Syndrome, a Rare Orphan Disease (HERO)
Methyl-CpG binding protein 2 (MECP2) is a dosage-sensitive, X-linked gene critical for central nervous system development and functional maintenance, which gain-of-function causes MECP2 duplication syndrome (MDS).
- Trial name
- HERO (NCT06615206)
- Testing
- HG204
- Where
- China
- Volunteers
- 6 people
- Sponsor
- HuidaGene Therapeutics Co., Ltd.
Relapsed or Refractory Mature Lymphoid Neoplasms
A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms
This is a Phase 1 multicenter, single-arm, open-label, dose escalation and dose expansion study of enhancer of zeste homolog 2 (EZH2 ) inhibitor SHR2554.
- Trial name
- NCT03603951
- Testing
- SHR2554
- Where
- China
- Volunteers
- 272 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Coronary Bifurcation Lesion
Efficacy and Safety of Sirolimus-Coated Spiral Balloon for Coronary Bifurcation Lesions
This is a multicenter, prospective randomized controlled study to evaluate the safety and effectiveness of Sirolimus-coated spiral balloon (SuperFlow®) versus Paclitaxel-coated balloon (Bingo™) in the treatment of coronary…
- Trial name
- NCT06618248
- Testing
- Sirolimus coated balloon angioplasty, Paclitaxel coated balloon angioplasty
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Dongguan TT Medical
Malignant Mesothelioma, Colorectal Cancer
Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors
This is a first-in-human, single-arm, open-label, dose escalation clinical study to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics, immunogenicity and preliminary efficacy of UCMYM802…
- Conditions
- Malignant Mesothelioma, Colorectal Cancer, Bile Duct Cancer, Rectal Cancer
- Trial name
- NCT06256055
- Testing
- UCMYM802 Injection
- Where
- China
- Volunteers
- 24 people
- Sponsor
- UTC Therapeutics Inc.
Neovascular Age-related Macular Degeneration
Gene Therapy(FT-003) for Wet AMD
The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of disposable vitreous injection of FT-003 in subjects with neovascular age-related Macular Degeneration (nAMD).
- Trial name
- NCT06492863
- Testing
- FT-003
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Frontera Therapeutics
Idiopathic Pulmonary Fibrosis
Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND001
Idiopathic pulmonary fibrosis (IPF) is a condition where the lungs are damaged and scarred with unknown reason, making breathing becomes increasingly difficult..
- Trial name
- NCT05657184
- Testing
- REGEND001
- Where
- 3 sites in China
- Volunteers
- 12 people
- Sponsor
- Regend Therapeutics
Relapsed or Refractory Acute Lymphoblastic Leukemia
Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration)
This study is a Phase II, single-arm, open-label, non-randomized, dose-escalation clinical trial to evaluate the efficacy and safety of ssCART-19 Cell Injection in the treatment of patients with CD19 positive Relapsed or…
- Trial name
- NCT06367114
- Testing
- ssCART-19, Fludarabine, Cyclophosphamide
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Colorectal Cancer
A Prospective Cohort Study on Colorectal Cancer Screening in Community Population
This study will validate the real world results of polygene methylation detection in colorectal cancer in a large prospective community cohort.
- Trial name
- NCT05485077
- Where
- China
- Volunteers
- 18,000 people, healthy volunteers welcome
- Sponsor
- Singlera Genomics Inc.
Systemic Lupus Erythematosus
A Study of RJMty19 in Refractory Systemic Lupus Erythematosus (SLE)
This study is an open-label, single-arm, dose escalation and dose expansion study to evaluate the safety, maximum tolerated dose, pharmacokinetic characteristics of allogeneic CD19-CAR-DNT cells (RJMty19) after infusion, and…
- Trial name
- NCT06340490
- Testing
- RJMty19 (CD19-CAR-DNT cells)
- Where
- 4 sites in China
- Volunteers
- 24 people
- Sponsor
- Guangdong Ruishun Biotech Co., Ltd